is tirzepatide a dual agonist GLP-1/GIP normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress InVivoSIM GIPR/GLP‑1R Dual Agonist (Tirzepatide

Side Effects The following is a list of common side effects

J., Pratt, S

For example, about 50 % of people on GLP-1 drugs lost 5 % or more of their weight, and roughly 17 % lost 10 % or more in clinical trials

Additionally, individuals on tirzepatide, especially those with diabetes, should monitor their blood sugar levels, as an infection itself can affect glucose control

Administration and Storage Tirzepatide is given as a subcutaneous injection, meaning it goes into the fatty tissue just under the skin

This includes adjusting the dose, delivery method, or formulation when a commercially available option is unavailable or unsuitable for a specific patient